Vogt L, et al. - By analyzing data from six large atorvastatin cardiovascular outcome trials with patients not selected for having kidney disease, researchers investigated if atorvastatin impacted kidney function deterioration and the link between individual kidney function slopes and cardiovascular outcome. In 30,621 patients, they analyzed slopes of serum creatinine reciprocals serving as measures of altered kidney function ([mg/dL]⁻¹/y). Three groups were defined according to treatment arms and included placebo (n=10,057), atorvastatin 10 mg daily (n=12,763), and 80 mg daily (n=7,801). In a dose-dependent manner, atorvastatin resulted in improvement of kidney function over time in patients at risk of or with cardiovascular disease. Findings revealed a strong association of kidney function improvement with lower cardiovascular risk in the three treatment groups.